PURPOSE OF REVIEW: This review describes the evolution of WHO guidelines for antiretroviral therapy (ART) in HIV-infected individuals, considering the key epidemiological, scientific, programmatic, and political changes over the last decade, and highlights the major trends for the management of the HIV disease in future guidelines revisions. RECENT FINDINGS: In the last few years, new evidence has emerged supporting the potential preventive benefit of ART in reducing HIV transmission. This, together with the potential clinical benefits of earlier initiation of therapy, has led to the consideration of the broader strategic use of ART, taking into account the clinical and public health benefit, and programmatic feasibility. SUMMARY: In 2002, WHO established its first guidelines for ART use, primarily focused on a public health approach for resource-limited settings. These recommendations were updated in 2003, 2006, and 2010, incorporating progressive changes reflecting progressive increase in the knowledge of HIV pathogenesis, development of new drugs and diagnostics, and increased experience of HIV treatment and prevention programs. The impact of several international political commitments and scale-up initiatives such as the 3 by 5 Initiative, Universal Access targets, and the Treatment 2.0 Strategy were also important drivers of the global response, increasing the treatment coverage and catalyzing the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS.
PURPOSE OF REVIEW: This review describes the evolution of WHO guidelines for antiretroviral therapy (ART) in HIV-infected individuals, considering the key epidemiological, scientific, programmatic, and political changes over the last decade, and highlights the major trends for the management of the HIV disease in future guidelines revisions. RECENT FINDINGS: In the last few years, new evidence has emerged supporting the potential preventive benefit of ART in reducing HIV transmission. This, together with the potential clinical benefits of earlier initiation of therapy, has led to the consideration of the broader strategic use of ART, taking into account the clinical and public health benefit, and programmatic feasibility. SUMMARY: In 2002, WHO established its first guidelines for ART use, primarily focused on a public health approach for resource-limited settings. These recommendations were updated in 2003, 2006, and 2010, incorporating progressive changes reflecting progressive increase in the knowledge of HIV pathogenesis, development of new drugs and diagnostics, and increased experience of HIV treatment and prevention programs. The impact of several international political commitments and scale-up initiatives such as the 3 by 5 Initiative, Universal Access targets, and the Treatment 2.0 Strategy were also important drivers of the global response, increasing the treatment coverage and catalyzing the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS.
Authors: Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: M Kumi Smith; Daniel Westreich; Huixin Liu; Lin Zhu; Lan Wang; Wensheng He; Jianping Zhou; William C Miller; Myron S Cohen; Ning Wang Journal: Clin Infect Dis Date: 2015-03-13 Impact factor: 9.079
Authors: Emily Adland; Paolo Paioni; Christina Thobakgale; Leana Laker; Luisa Mori; Maximilian Muenchhoff; Anna Csala; Margaret Clapson; Jacquie Flynn; Vas Novelli; Jacob Hurst; Vanessa Naidoo; Roger Shapiro; Kuan-Hsiang Gary Huang; John Frater; Andrew Prendergast; Julia G Prado; Thumbi Ndung'u; Bruce D Walker; Mary Carrington; Pieter Jooste; Philip J R Goulder Journal: PLoS Pathog Date: 2015-06-15 Impact factor: 6.823
Authors: Claire L Gordon; Allen C Cheng; Paul U Cameron; Michael Bailey; Suzanne M Crowe; John Mills Journal: PLoS One Date: 2015-06-25 Impact factor: 3.240
Authors: More Mungati; Mutsa Mhangara; Janet Dzangare; Owen Mugurungi; Tsitsi Apollo; Elizabeth Gonese; Peter H Kilmarx; Christine C Chakanyuka-Musanhu; Gerald Shambira; Mufuta Tshimanga Journal: J Epidemiol Res Date: 2016
Authors: Ashwin Vasan; Andrew Ellner; Stephen D Lawn; Sandy Gove; Manzi Anatole; Neil Gupta; Peter Drobac; Tom Nicholson; Kwonjune Seung; David C Mabey; Paul E Farmer Journal: BMC Med Date: 2014-01-14 Impact factor: 8.775